CEL-SCI Corporation (NYSEMKT:CVM) on Mar. 4 announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. CEL-SCI Corporation (NYSEMKT:CVM) shares after opening at $1.44 moved to $1.57 on last trade day and at the end of the day closed at $1.53. Company price to sales ratio in past twelve months was calculated as 245.90 and price to cash ratio as 5.46. CEL-SCI Corporation (NYSEMKT:CVM) showed a positive weekly performance of 8.51%.
JA Solar Holdings Co. (NASDAQ:JASO) was the recipient of some unusual options trading activity on Friday. Traders acquired 12,561 call options on the stock, AR Network reports. This represents an increase of 208% compared to the average daily volume of 4,076 call options. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) shares advanced 8.25% in last trading session and ended the day on $11.42. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) return on equity ratio is recorded as -26.00% and its return on assets is -9.60%. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) yearly performance is 157.21%.
CytRx Corporation (NASDAQ:CYTR) on Mar. 12 announced that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials. A full clinical hold is an order that the FDA issues to a trial sponsor to suspend an ongoing clinical trial or delay a proposed trial. CytRx Corporation (NASDAQ:CYTR) shares moved down -0.48% in last trading session and was closed at $4.15, while trading in range of $3.61 – $4.17. CytRx Corporation (NASDAQ:CYTR) year to date (YTD) performance is -33.81%.
Geron Corp. (NASDAQ:GERN), a biotechnology company with no marketed products, plunged after U.S. regulators halted development of its only experimental drug, imetelstat for blood disorders, because of the possibility of liver damage. Geron Corporation (NASDAQ:GERN) weekly performance is -59.60%. On last trading day company shares ended up $1.83. Geron Corporation (NASDAQ:GERN) distance from 50-day simple moving average (SMA50) is -61.33%. Analysts mean target price for the company is $2.00.